1. Introduction {#s1}
===============

Atrial fibrillation (AF) is very common in elderly patients.[@b1]--[@b3] Thus, more than 10% of patients aged 70 years or older have AF, number that reaches 18% in those individuals aged 80 years or older.[@b1] Overall, patients with AF have a high number of comorbidities.[@b1]--[@b4] Remarkably, elderly patients have some additional particularities, including cognitive impairment, dependency, falls or frailty that markedly increase the risk of developing complications in this population.[@b5]--[@b8] In fact, compared with younger patients, elderly patients with AF have an increased risk of death, stroke and bleeding.[@b9]

Except when contraindicated, AF patients aged 75 years or older should be chronically anticoagulated.[@b5],[@b10],[@b11] Unfortunately, many elderly patients do not receive oral anticoagulation regardless thromboembolic or bleeding risk, due to a number of causes that include frailty, cognitive impairment, disability, concern about bleeding risk, and classically, the well known limitations of vitamin K antagonists (VKA), such as the narrow therapeutic window, periodic monitoring of anticoagulation activity, frequent dose adjustments, interactions with many drugs, etc.[@b5],[@b12] Under anticoagulation leads to a higher risk of stroke and death in these patients.[@b13]

Direct oral anticoagulants (DOACs) overcome the most relevant limitations of VKA and overall, seem more effective and safer.[@b14] It has been reported that the efficacy and safety of DOACs compared with VKA are independent of age, and due to the lower risk of intracranial hemorrhage associated with DOACs, they may be a safer choice in elderly patients.[@b15]

The most relevant information about the efficacy and safety of oral anticoagulants comes from clinical trials in which data regarding elderly patients are limited.[@b14],[@b15] Observational studies and registries may allow to determine the clinical profile and management of elderly patients with AF in clinical practice.[@b16] Unfortunately, the information currently available about this issue according to dependency, frailty and cognitive impairment is clearly insufficient.

The ESPARTA study was performed to determine the degree of adherence to the recommendations performed by the Therapeutic Positioning Report of the Spanish Medicine and Sanitary Products Agency about the treatment with oral anticoagulants, in patients aged ≥ 75 years with nonvalvular atrial fibrillation (NVAF) treated with oral anticoagulants, attended in Spanish Internal Medicine departments in clinical practice.[@b17] In this study, the bio-demographic data, clinical profile and antithrombotic treatment according to the degree of dependency, fragility and cognitive impairment were analyzed.

2. Methods {#s2}
==========

ESPARTA was an observational, cross-sectional and multi-center study that consecutively included patients aged ≥ 75 years old, with a diagnosis of NVAF, attended in Internal Medicine units (hospitalization or outpatients) in Spain, treated with oral anticoagulants ≥ 3 months previous the inclusion and that had provided signed informed consent. Patients with mitral stenosis, prosthetic valve, or valvuloplasty, that had participated in clinical trials involving the use of DOACs in the six months before inclusion, or that were unable to understand or fulfill the questionnaires of the study were excluded. The study was approved by the Clinical Research Ethics Committee of Hospital Universitario de la Princesa de Madrid and endorsed by the local ethic committees of the participating centers.[@b17]

The study was performed in 63 Internal Medicine units throughout Spain according to clinical practice. The participating sites were representative sample of all such sites in Spain. Patients were included between October 2015 and March 2016. The study consisted in a single visit. No specific diagnostic or therapeutic interventions were performed due to the study. The biodemographic and clinical data were collected from the medical history during the physician interview and recorded by each investigator into an electronic case report form specifically designed for this study.[@b17]

Data from biodemographic variables (age, sex, place where patients lived, degree of dependency, type of AF, body weight), cardiovascular risk factors (hypertension, diabetes), vascular conditions (heart failure, ischemic stroke, stable angina, peripheral artery disease, renal insufficiency, systemic embolism) and blood analysis (creatinine clearance, hemoglobin) were recorded.[@b17]

The thromboembolic risk was determined by the CHADS~2~ and CHA~2~DS~2~-VASc scales and the risk of bleeding by the HAS-BLED scale.[@b10] The type of oral anticoagulant (VKA *vs.* DOACs) was recorded.

Polymedication was defined as the regular intake of at least five tablets daily at the moment of the visit. Adherence to treatment with oral anticoagulants was determined by using the Morisky-Green test. Good adherence was defined as an average adherence to oral anticoagulation of ≥ 80%.[@b18] Partial dependency was considered when the patient needed help for at least one of the following activities: personal care, eating, getting dressed, or moving and total dependency when the patient needed help for all previous activities. Cognitive function was assessed by using the Pfeiffer\'s test, defining the presence of cognitive impairment as having a score ≥ 3.[@b19] Fragility was determined with the FRAIL scale. The fragile patient was defined as having a score ≥ 3 in the FRAIL scale.[@b20] Comorbidity was determined according to the Charlson comorbidity index. High comorbidity was defined as having a Charlson comorbidity index ≥ 3.[@b21]

For the descriptive analysis, quantitative variables were described with measures of central tendency and dispersion (mean ± SD) and qualitative variables were described as absolute (*n*) and relative (%) frequencies. In the bivariate analysis to compare two means, the nonparametric Mann--Whitney *U* test was performed. To compare percentages, the chi-square test or Fisher test were used, according to the sample size.

Stepwise binary logistic regression analyses were performed to identify those clinical variables associated with dependency, fragility, cognitive impairment and dependency. Those variables with a *P*-value \< 0.10 in the univariate analysis were included in the multivariate analyses. Odds ratios and their respective 95% confidence intervals were used to describe the results of the multivariate analyses. Statistical significance was set at a *P*-value \< 0.05. The statistical analysis was performed using the SAS statistics package, version 9.4.

3. Results {#s3}
==========

A total of 837 patients (mean age 83.0 ± 5.0 years; 48.7% men; 83.3% permanent AF) were included in the study. Patients had a great number of comorbidities (84.3% had hypertension, 62.7% heart failure, 39.1% diabetes and 19.2% prior ischemic stroke). Patients had a high thromboembolic risk (mean CHADS~2~ score 3.2 ± 1.2; mean CHA~2~DS~2~-VASc score 5.0 ± 1.4), but only 28.9% had a high risk of bleeding ([Table 1](#jgc-15-04-268-t01){ref-type="table"}). Overall, 72.1% of patients showed a good adherence to anticoagulant therapy, without significant differences among the type of oral anticoagulant (73.0% in patients taking AVK *vs.* 70.1% in patients taking DOACs; *P* = NS).

###### Clinical profile of patients according to the degree of dependency, fragility and cognitive impairment.

  Variables                               Overall (*n =* 837)   Autonomous (*n =* 465)   Dependent (*n =* 372)      *P*      No fragile (*n =* 472)   Fragile (*n =* 360)      *P*      No cognitive impairment (*n =* 567; 67.7%)   Cognitive impairment (*n =* 270)      *P*
  -------------------------------------- --------------------- ------------------------ ----------------------- ----------- ------------------------ --------------------- ----------- -------------------------------------------- ---------------------------------- -----------
  **Biodemographic data**                                                                                                                                                                                                                                              
   Age, yrs                                   83.0 ± 5.0              81.8 ± 4.8              84.5 ± 4.9         \< 0.0001         82.4 ± 5.0             83.8 ± 4.9        \< 0.0001                   82.3 ± 4.9                              84.4 ± 5.0              \< 0.0001
   Gender male                                   48.7%                  57.0%                    38.4%           \< 0.0001           55.3%                   40.3%          \< 0.0001                     53.8%                                   38.1%                 \< 0.0001
   Place where patients live                                                                                                                                                                                                                                           
    Home                                         93.8%                  97.4%                    89.2%           \< 0.0001           96.6%                   90.0%          \< 0.0001                     96.5%                                   88.1%                 \< 0.0001
    Nursing home                                 6.2%                    2.6%                    10.8%             3.4%              10.0%                   3.5%             11.9%                                                                                    
   No dependency                                 55.6%                   100%                      0             \< 0.0001           72.0%                   34.4%          \< 0.001                      71.3%                                   22.6%                 \< 0.0001
   Permanent atrial fibrillation                 83.3%                  80.0%                    87.4%             0.01              81.4%                   85.8%             NS                         80.8%                                   88.5%                   0.006
   Body weight, kg                            73.7 ± 13.9            74.0 ± 13.8              73.3 ± 14.1           NS            73.4 ± 13.5             74.1 ± 14.5          NS                      74.5 ± 14.0                             71.9 ± 13.6                0.03
  **Cardiovascular risk factors**                                                                                                                                                                                                                                      
   Hypertension                                  84.3%                  81.3%                    88.2%             0.006             82.4%                   86.9%             NS                         83.6%                                   85.9%                    NS
   Diabetes mellitus (%)                         39.1                    35.3                    43.8              0.01              34.7%                   44.4%            0.004                       38.6%                                   40.0%                    NS
  **Cardiovascular disease**                                                                                                                                                                                                                                           
   Heart failure                                 62.7%                  52.9%                    75.0%           \< 0.0001           51.3%                   77.5%          \< 0.0001                     57.0%                                   74.8%                 \< 0.0001
   Ischemic stroke                               19.2%                  13.8%                    26.1%           \< 0.0001           16.1%                   23.1%            0.01%                       16.4%                                   25.2%                   0.002
   Stable angina                                 9.0%                    8.0%                    10.2%              NS                6.1%                   12.5%            0.001                        8.5%                                   10.0%                    NS
   Peripheral artery disease                     8.1%                    8.0%                    8.3%               NS                8.5%                   7.8%              NS                          9.2%                                    5.9%                    NS
   Renal insufficiency\*                         7.9%                    7.1%                    8.9%               NS                5.7%                   10.6%            0.01                         6.7%                                   10.4%                    NS
   Systemic embolism                             2.5%                    1.9%                    3.2%               NS                1.9%                   3.3%              NS                          2.3%                                    3.0%                    NS
   Creatinine clearance, mL/min               50.7 ± 21.9            53.2 ± 22.0              47.4 ± 21.3         0.0002          52.4 ± 20.9             48.7 ± 22.9         0.001                    52.2 ± 21.1                             47.4 ± 23.2               0.0002
  **Thromboembolic and bleeding risk**                                                                                                                                                                                                                                 
   Mean CHADS~2~ score                         3.2 ± 1.2              3.0 ± 1.1                3.6 ± 1.2         \< 0.0001         3.0 ± 1.2               3.6 ± 1.2        \< 0.0001                   3.1 ± 1.1                               3.5 ± 1.3                0.0001
    High thromboembolic risk                     94.7%                  91.8%                    98.4%           \< 0.0001           92.8%                   97.2%            0.004                       93.7%                                   97.0%                   0.04
   Mean CHA~2~DS~2~-VASc score                 5.0 ± 1.4              4.7 ± 1.3                5.5 ± 1.4         \< 0.0001         4.7 ± 1.3               5.4 ± 1.4        \< 0.0001                   4.8 ± 1.3                               5.4 ± 1.5               \< 0.0001
    High thromboembolic risk                     100%                    100%                    100%               NS                100%                   100%              NS                          100%                                    100%                    NS
   Mean HAS-BLED score                         2.1 ± 0.9              1.9 ± 0.9                2.2 ± 0.9         \< 0.0001         1.9 ± 0.9               2.3 ± 1.0        \< 0.0001                   2.0 ± 0.9                               2.2 ± 0.9                0.0006
    High bleeding risk                           28.9%                  22.5%                    36.9%           \< 0.0001           21.6%                   37.4%          \< 0.0001                     26.2%                                   34.5%                   0.01
    Prior bleeding                               17.6%                  17.6%                    17.5%              NS               15.7%                   19.4%             NS                         19.0%                                   14.4%                    NS
  **Other conditions**                                                                                                                                                                                                                                                 
   Hemoglobin, g/dL                           12.4 ± 2.0              12.9 ± 2.0              11.9 ± 1.8         \< 0.0001         12.9 ± 1.8             11.9 ± 2.0        \< 0.0001                   12.7 ± 2.0                              11.9 ± 1.8              \< 0.0001
   Pfeiffer\'s test                            1.9 ± 2.1              1.0 ± 1.4                3.1 ± 2.3         \< 0.0001         1.4 ± 1.9               2.5 ± 2.3        \< 0.0001                   0.6 ± 0.8                               4.5 ± 1.6               \< 0.0001
   Cognitive impairment                          32.3%                  13.1%                    56.2%           \< 0.0001           20.6%                   47.5%          \< 0.0001                       0                                      100%                 \< 0.0001
   FRAIL scale                                 2.1 ± 1.4              1.6 ± 1.3                2.7 ± 1.3         \< 0.0001         1.0 ± 0.8               3.5 ± 0.6        \< 0.0001                   1.8 ± 1.4                               2.7 ± 1.3               \< 0.0001
   Fragility                                     43.3%                  26.7%                    64.1%           \< 0.0001             0                     100%           \< 0.0001                     33.5%                                   63.8%                 \< 0.0001
   Charlson comorbidity index                  2.7 ± 1.9              2.4 ± 1.9                3.1 ± 1.9         \< 0.0001         2.3 ± 1.9               3.3 ± 1.9        \< 0.0001                   2.5 ± 1.9                               3.2 ± 2.0               \< 0.0001
   Falls                                         25.1%                  17.8%                    34.1%           \< 0.0001           20.6%                   30.6%           0.0009                       22.4%                                   30.7%                   0.009
   Polymedication                                91.5%                  88.2%                    95.7%            0.0001             87.9%                   96.4%          \< 0.0001                     89.6%                                   95.6%                   0.003
   Adherence to treatment                        72.1%                  71.8%                    72.5%              NS               74.8%                   68.3%            0.03                        75.6%                                   64.8%                   0.001

Data are presented as mean ± SD or percent unless other indicated. \*Renal insufficiency: chronic dialysis, renal transplantation or serum creatinine ≥ 2.26 mg/dL. NS: not significant.

The clinical profile of patients according to the degree of dependency, fragility and cognitive impairment was analyzed in [Table 1](#jgc-15-04-268-t01){ref-type="table"}. Overall, 465 (55.6%) of patients were completely autonomous, and 372 (44.4%) patients had some degree of dependency (total or partial). Compared with those patients that were autonomous, those patients with dependency were older, lived more commonly at nursing homes, had more comorbidities (hypertension, diabetes, heart failure and ischemic stroke), a worse renal function and a higher thromboembolic and bleeding risk. Anemia and polymedication were more common in patients with dependency. Scores in Pfeiffer\'s test, FREIL scale and Charlson comorbidity index were also worse in patients with dependency ([Table 1](#jgc-15-04-268-t01){ref-type="table"}).

A total of 360 (43.3%) patients were fragile. Fragile patients were older, had more comorbidities and a higher risk of falls and thromboembolic and bleeding events. The majority (65.6%) of frail patients had some degree of dependency. Cognitive impairment was more common in frail patients (47.5% *vs*. 20.6%; *P* \< 0.0001) ([Table 1](#jgc-15-04-268-t01){ref-type="table"}). Overall, 270 (32.3%) patients had cognitive impairment. Compared with patients without cognitive impairment, patients with cognitive impairment were older, lived more frequently at nursing homes, the degree of dependency was higher, had more heart failure, ischemic heart disease, anemia and risk of falls, a worse renal function and higher thromboembolic and bleeding risk. Scores in Pfeiffer\'s test, FREIL scale and Charlson comorbidity index were also worse in patients with cognitive impairment ([Table 1](#jgc-15-04-268-t01){ref-type="table"}).

Overall, falls occurred in 25.1% of patients, being more common among dependent patients (34.1% *vs*. 17.8%; *P* \< 0.0001), fragile patients (30.6% *vs*. 20.6%; *P* = 0.0009) and patients with cognitive impairment (30.7% *vs*. 22.4%; *P* = 0.009) ([Table 1](#jgc-15-04-268-t01){ref-type="table"}).

Multivariate analyses were performed to assess those variables that were independently associated with the presence of dependency, fragility, or cognitive impairment ([Table 2](#jgc-15-04-268-t02){ref-type="table"}). A higher thromboembolic risk, falls, higher scores in FRAIL scale and Pfeiffer\'s test, age and anemia increased the risk of dependency. Dependency, stable angina, heart failure, female sex, cognitive impairment, a higher Charlson comorbidity index and anemia were independently associated with the presence of fragility. Dependency, living at nursing homes, higher scores in FRAIL scale and Charlson comorbidity index, anemia and poor adherence to medication were independently associated with cognitive impairment.

###### Variables associated with dependency, fragility and cognitive impairment.

                                                           OR     95% confidence interval      *P*
  ----------------------------------------------------- -------- ------------------------- -----------
  **Variables associated with dependency**                                                 
  CHADS~2~ (high *vs*. intermediate risk)                8.197         1.786--38.461         0.0068
  Falls (yes *vs*. no)                                   1.841         1.188--2.853          0.0063
  FRAIL scale                                            1.644         1.413--1.914         \< 0.0001
  Pfeiffer\'s test                                       1.627         1.451--1.824         \< 0.0001
  Age, yrs                                               1.060         1.019--1.103          0.0036
  Hemoglobin, g/dL                                       0.832          0.748-0.924          0.0006
  **Variables associated with fragility**                                                  
  Dependency                                                                               
   Autonomous                                             \--               \--             \< 0.0001
   Partial dependency                                    2.830         1.879--4.124        
   Total dependency                                      6.813         2.437--19.047       
  Stable angina (yes *vs*. no)                           2.371         1.285--4.376          0.0058
  Heart failure (yes *vs*. no)                           2.080         1.372--3.153          0.0006
  Sex (women *vs*. men)                                  1.889         1.308--2.728          0.0007
  Cognitive impairment (yes *vs*. no)                    1.528         1.042--2.398          0.0309
  Charlson comorbidity index                             1.156         1.041--1.159          0.0071
  Hemoglobin, g/dL                                       0.840         0.769--0.840          0.0011
  **Variables associated with cognitive impairment**                                       
  Dependency                                                                               
   Autonomous                                             \--               \--             \< 0.0001
   Partial dependency                                    5.001         3.276--7.633        
   Total dependency                                      15.890        6.279--40.239       
  Place where patients live (nursing home *vs*. home)    2.483         1.095--5.635          0.0295
  FRAIL scale                                            1.174         1.003--1.374          0.0458
  Charlson comorbidity index                             1.120         1.011--1.241          0.0295
  Hemoglobin                                             0.899         0.810--0.998          0.0459
  Adherence (good *vs*. poor)                            0.575         0.376--0.881          0.0109

The use of antithrombotic treatment according to the degree of dependency, frailty and cognitive impairment was also analyzed ([Table 3](#jgc-15-04-268-t03){ref-type="table"}). VKA were the most common oral anticoagulant prescribed in the overall study population, reaching 70.8% of patients. The remaining 29.2% of patients were taking DOACs. In addition to anticoagulant therapy, 9.7% of patients were taking oral antiplatelets. This distribution was independent of the degree of dependency and the presence of fragility, but there was a trend to a higher prescription of VKA in those patients with cognitive impairment (75.2% *vs*. 68.8%; *P* = 0.05) and a lower prescription of DOACs (24.8% *vs*. 31.2%; *P* = 0.05).

###### Type of oral anticoagulant according to dependency, frailty and cognitive impairment.

  Variable        Overall (*n =* 837)   Autonomous (*n =* 465; 55.6%)   Dependent (*n =* 372; 44.4%)   *P*    No fragile (*n =* 472; 56.7%)   Fragile (*n =* 360; 43.3%)    *P*     No cognitive impairment (*n =* 567; 67.7%)   Cognitive impairment (*n =* 270; 32.3%)   *P*
  -------------- --------------------- ------------------------------- ------------------------------ ------ ------------------------------- ---------------------------- -------- -------------------------------------------- ----------------------------------------- ------
  VKA                    70.8                       70.1                            71.8                NS                70.1                           71.7                NS                        68.8                                       75.2                     0.05
  DOACs                  29.2                       29.9                            28.2                NS                29.9                           28.3                NS                        31.2                                       24.8                     0.05
   Dabigatran            19.7                       19.4                            20.0               0.01               22.7                           15.7              0.0005                      16.9                                       26.9                     0.02
   Rivaroxaban           45.1                       52.5                            35.2               52.5               35.3                           50.3               31.3                                                                                          
   Apixaban              35.2                       28.1                            44.8               24.8               49.0                           32.8               41.8                                                                                          

DOACs: direct oral anticoagulants; NS: not significant; VKA: vitamin K antagonists.

4. Discussion {#s4}
=============

In the ESPARTA study, a wide sample of anticoagulated elderly patients with AF was included. These patients had a high thromboembolic risk (CHA~2~DS~2~-VASc 5.0), a high number of comorbidities, but less than 30% of patients had a high bleeding risk. This is in line with previous reports.[@b22] In the ESPARTA study, approximately 44% of patients had some degree of dependency, 43% of patients were fragile, and 32% had cognitive impairment. Despite some studies have analyzed the clinical profile and management of elderly patients with AF, the majority of these studies have focused only on one of these conditions, but not on all at the same time.[@b7],[@b23] In our study, patients with any of these conditions were older and had a worse clinical profile, with more comorbidities and a higher thromboembolic and bleeding risk. In addition, as shown in the multivariate analyses, all these conditions were related, since the presence of one of them promoted the presence of the others. A number of studies have analyzed the impact of fragility in this specific population. Similar to our data, these studies have reported that frail subjects are older, have more comorbidities, and a higher risk of stroke and mortality.[@b8],[@b23] Cognitive impairment is more common in this population.[@b4] Remarkably, the identification of these conditions is mandatory, since it has been shown that the baseline functional status is the strongest predictor for in-hospital mortality in elderly AF patients.[@b24] In addition, frailty status is positively associated with the CHA~2~DS~2~-VASc and the HAS-BLED scales, and it may provide additional prognostic value in this population.[@b25]

Polymedication is very common in elderly patients with AF, particularly when dependency, frailty or cognitive impairment are present, as our study showed. It has been reported that it may be more important the multifactorial medical profile and functional status rather than cognitive impairment when prescribing long-term oral anticoagulation.[@b26] Importantly, in our study, medication adherence to anticoagulant therapy was lower in frailty patients and in patients with cognitive impairment. Since drug-drug interactions are more frequent in this population as well as making mistakes while taking the medication,[@b6] when any of these conditions (dependency, frailty and/or cognitive impairment) are present, additional support may be required for these patients.[@b5]

Overall, falls were reported in 25% of patients, increasing approximately to one third among dependent patients, fragile patients and patients with cognitive impairment. However, in the multivariate analysis, falls only remained as an independent variable in the case of dependency. Traditionally, one of the causes that have limited the use of oral anticoagulants has been the risk of falls. However, it has been shown that although more caution should be taken in these patients, since the risk of stroke is markedly increased in this population, overall, oral anticoagulation should be considered.[@b27] In this context, due to the better benefit/risk profile of DOACs over VKA, it seems a better choice the use of DOACs in this setting.[@b28]

In our study, anemia was independently associated with dependency, frailty and cognitive impairment. Previous studies have shown the same results, not only in individuals with AF, but also in the general elderly population.[@b29] As a result, low hemoglobin levels among elderly patients may alert clinicians about the increased risk of dependency, frailty or cognitive impairment that these individuals have.

Unless contraindicated, every elderly patient with AF should receive long-term oral anticoagulation.[@b10] Our study showed that in patients with dependency, frailty or cognitive impairment, the thromboembolic risk was very high, but only 34%--37% of patients had a high risk of bleeding. Similarly, other authors have shown in frail patients with AF that stroke risk is high and bleeding risk levels comparatively low.[@b30] However, although some studies have suggested an increase of anticoagulation in frail octogenarian patients, many elderly patients do not receive anticoagulant therapy. For example, it has been reported that in more than 40% of older adults with AF after acute ischemic stroke, patients are not discharged with an oral anticoagulant. In this study, fall risk, poor prognosis, older age, and dementia have been shown as predictors of not prescribing oral anticoagulants.[@b31] Importantly, none of these variables should be considered as an absolute contraindication for anticoagulation by themselves.[@b5] This is very relevant, since discontinuation of anticoagulation in elderly patients with AF is frequent and it is associated with increased risks of death and adverse events.[@b32]

In our study, the majority of patients were anticoagulated with VKA, regardless dependency or frailty, and showed a trend to a higher prescription of VKA in those patients with cognitive impairment. However, considering that cognitive disorders in patients with AF significantly reduce the efficacy of VKA therapy[@b33] and that DOACs exhibit a better beneficial/risk ratio than VKA in elderly patients, not only in clinical trials but also in "real-life" studies,[@b15],[@b34]--[@b37] the prescription of VKA instead of DOACs in our study was excessively high. In fact, the prescription of DOACs in elderly patients with AF in Spain is lower than in other similar countries.[@b38] This may be related, at least in part, with the administrative restrictions for the prescription of DOACs in Spain.

This study has some limitations that should be commented. Since this study has an observational and cross-sectional design, not all potential confounders can be controlled. However, this design may represent clinical practice more accurately. In addition, as in this study only anticoagulated elderly patients (≥ 75 years old) were included, the information provided by our data cannot be extended to the whole population with AF, or with different healthcare system. Moreover, despite meticulousness in recording data, because dependency, frailty, cognitive impairment and comorbidity were defined using only one scale in defining them, this could translate into an underdiagnosis of some patients.

In conclusion, the elderly patients with nonvalvular AF treated with oral anticoagulants in Internal Medicine departments in Spain have a high thromboembolic risk, a high number of comorbidities, but less than 30% of patients have a high risk of bleeding. Approximately 44% of patients have some degree of dependency, 43% are fragile, and 32% have cognitive impairment. Patients with any of these conditions are older and have a worse clinical profile. All these conditions are related, since the presence of one of them promotes the presence of the others. The majority of patients are anticoagulated with VKA, regardless dependency or frailty, but with a trend to a higher prescription of VKA in those patients with cognitive impairment. According with previous trials, our study showed that in patients with dependency, frailty or cognitive impairment, the thromboembolic risk was very high, but only one third of these patients had a high risk of bleeding. So unless strong and real contraindication, every elderly patient with AF should receive long-term oral anticoagulation.
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